NASDAQ:AKTX - Akari Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.98 +0.07 (+3.66 %)
(As of 01/17/2019 04:00 PM ET)
Previous Close$1.91
Today's Range$1.91 - $1.99
52-Week Range$1.56 - $3.90
Volume4,272 shs
Average Volume27,969 shs
Market Capitalization$30.51 million
P/E Ratio-7.07
Dividend YieldN/A
Beta-4.65
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.

Receive AKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKTX
CUSIPN/A
Phone44-20-8004-0270

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.46 per share

Profitability

Net Income$-35,390,000.00

Miscellaneous

Employees17
Market Cap$30.51 million
OptionableNot Optionable

Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions

What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics PLC (NASDAQ:AKTX) posted its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter. View Akari Therapeutics' Earnings History.

When is Akari Therapeutics' next earnings date?

Akari Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 20th 2019. View Earnings Estimates for Akari Therapeutics.

What price target have analysts set for AKTX?

2 brokerages have issued 12 month price targets for Akari Therapeutics' stock. Their predictions range from $3.00 to $8.00. On average, they anticipate Akari Therapeutics' stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 177.8% from the stock's current price. View Analyst Price Targets for Akari Therapeutics.

What is the consensus analysts' recommendation for Akari Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akari Therapeutics.

Has Akari Therapeutics been receiving favorable news coverage?

News stories about AKTX stock have been trending negative on Thursday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akari Therapeutics earned a daily sentiment score of -2.8 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future.

Who are some of Akari Therapeutics' key competitors?

Who are Akari Therapeutics' key executives?

Akari Therapeutics' management team includes the folowing people:
  • Dr. Ray Prudo, Exec. Chairman (Age 73)
  • Mr. Clive Richardson, COO, Director & Interim CEO (Age 53)
  • Mr. Dov Elefant, Chief Financial Officer (Age 51)
  • Dr. Miles Nunn, Chief Scientific Officer
  • Dr. Wynne Weston-Davies MRCS, LRCP, MBBS, FRCS, ECFMG, Medical Director

How do I buy shares of Akari Therapeutics?

Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $1.98.

How big of a company is Akari Therapeutics?

Akari Therapeutics has a market capitalization of $30.51 million. The biopharmaceutical company earns $-35,390,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Akari Therapeutics employs 17 workers across the globe.

What is Akari Therapeutics' official website?

The official website for Akari Therapeutics is http://www.akaritx.com.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREE, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 44-20-8004-0270 or via email at [email protected]


MarketBeat Community Rating for Akari Therapeutics (NASDAQ AKTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  291
MarketBeat's community ratings are surveys of what our community members think about Akari Therapeutics and other stocks. Vote "Outperform" if you believe AKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel